PHCC Priority Healthcare b (MM)

Priority Healthcare Selected as a Provider of Ventavis(TM) LAKE MARY, Fla., Feb. 22 /PRNewswire-FirstCall/ -- Priority Healthcare Corporation (NASDAQ:PHCC) announced that it has been selected by CoTherix, Inc. (NASDAQ:CTRX) to be a full-service specialty pharmacy provider of Ventavis(TM) (iloprost) Inhalation Solution. The Food and Drug Administration approved Ventavis(TM) on December 29, 2004 for the treatment of pulmonary arterial hypertension (World Health Organization Group I) or PAH, in patients with NYHA Class III or IV symptoms. "We are pleased to have been selected by CoTherix as one of the limited network of specialty pharmacies that will have access to Ventavis," stated Steve Cosler, President and CEO. "Adding this important product to our growing portfolio of treatment options for PAH patients facilitates better continuity of care for the patients and physicians involved with this community. This patient population requires a high degree of nursing support which we are able to provide through our 29 pharmacy locations nationwide." Physicians prescribing Ventavis for their patients can call Priority Healthcare's dedicated pulmonary hypertension call center at 866-4PH-TEAM to receive a comprehensive reimbursement profile for their patients and other clinical support services that are provided as part of the Priority Healthcare CaringPath(SM) disease management program for PAH. IMPORTANT SAFETY INFORMATION: In clinical studies, common adverse reactions due to Ventavis included: vasodilation (flushing), cough, headache, flu syndrome, nausea, trismus, hypotension, insomnia and syncope. Because of the risk of syncope, vital signs should be monitored while initiating Ventavis. Dose adjustments or a change in therapy should be considered if exertional syncope occurs. Ventavis should not be initiated in patients with systolic blood pressure lower than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur. Ventavis has not been evaluated in patients with chronic obstructive pulmonary disease (COPD), severe asthma, or with acute pulmonary infections. About Priority Healthcare Corporation Priority Healthcare Corporation is a national specialty pharmacy and distributor that provides biopharmaceuticals, complex therapies, and related disease treatment services. Priority Healthcare provides comprehensive programs for patients, payors, physicians, and pharmaceutical manufacturers for a growing number of disease states including cancer, hepatitis C, respiratory and pulmonary conditions, infertility, rheumatoid arthritis, hemophilia, multiple sclerosis, Parkinson's disease, and macular degeneration. Additional information regarding Priority Healthcare is available online at http://www.priorityhealthcare.com/ Certain statements included in this press release, which are not historical facts, are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our expectations or beliefs and involve certain risks and uncertainties, including those described in our public filings with the United States Securities and Exchange Commission; also including, but not limited to, changes in interest rates, competitive pressures, changes in customer mix, changes in third party reimbursement rates, financial stability of major customers, changes in government regulations or the interpretation of these regulations, changes in supplier relationships, growth opportunities, cost savings, revenue enhancements, synergies and other benefits anticipated from acquisition transactions, difficulties relative to integrating acquired businesses, the accounting and tax treatment of acquisitions, and asserted and unasserted claims, which could cause actual results to differ from those in the forward-looking statements. The forward-looking statements by their nature involve substantial risks and uncertainties, certain of which are beyond our control, and actual results may differ materially depending on a variety of important factors. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date herein. http://www.newscom.com/cgi-bin/prnh/20030417/PHCLOGODATASOURCE: Priority Healthcare Corporation CONTACT: Stephen Saft, Chief Financial Officer of Priority Healthcare Corporation, +1-407-804-6700 Web site: http://www.priorityhealthcare.com/

Copyright